National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates™: NCCN Guidelines® & NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Non-Hodgkin’s Lymphomas. These NCCN Guidelines® are currently available as Version 2.2016. 

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    • First-line therapy for frail patients with significant comorbidity (CSLL-D 1 of 7)
      • "Ibrutinib" was added with a category 1 designation.
    • CLL without del (11q) or del (17p)/TP53 mutation (CSLL-D 1 of 7 and CSLL-D 2 of 7)
      • First-line therapy for patients ³70 years and younger patients with significant comorbidities
        • "Ibrutinib" was added with a category 1 designation.
      • Second-line extended dosing
        • "Ofatumumab maintenance (for complete or partial response after relapsed or refractory therapy)" was added with a category 2B designation.
    • CLL with del (17p)/TP53 mutation (CSLL-D 3 of 7)
      • Second-line extended dosing
        • "Ofatumumab maintenance (for complete or partial response after relapsed or refractory therapy)" was added with a category 2B designation.
    • CLL with del (11q) (CSLL-D 4 of 7 and CSLL-D 5 of 7)
      • First-line therapy for patients ³70 years and younger patients with significant comorbidities
        • "Ibrutinib" was added with a category 1 designation.
      • Second-line extended dosing
        • "Ofatumumab maintenance (for complete or partial response after relapsed or refractory therapy)" was added with a category 2B designation

*For your reference, the previous update (Version 1.2016) to the NCCN Guidelines for Non-Hodgkin’s Lymphomas, published on November 24, 2015, is available at the following link: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.

To access the NCCN Biomarkers Compendium™, please visit NCCN.org/biomarkers.

To view the NCCN Guidelines for Patients®, please visit NCCN.com/patients.

Free NCCN Guidelines apps for iPhone, iPad, and Android tablets are now available! Visit NCCN.org/apps

About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300

Fort Washington, PA 19034

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2016 National Comprehensive Cancer Network. All Rights Reserved.